SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): March 9, 2016
Arbutus Biopharma Corporation
(Exact Name of Registrant as Specified in Charter)
|BRITISH COLUMBIA, CANADA ||001-34949||980597776|
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(I.R.S. Employer Identification Number)|
|100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8|
|(Address of Principal Executive Offices) (Zip Code)|
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
|Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:|
| ||[ ]|| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
| ||[ ]|| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
| ||[ ]|| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
| ||[ ]|| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 2.02. Results of Operations and Financial Condition.
On March 9, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1. Press release dated March 9, 2016
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ||Arbutus Biopharma Corporation|
| || || |
| || || |
|Date: March 9, 2016||By: ||/s/ Bruce G. Cousins |
| || ||Name: Bruce G. Cousins|
| || ||Title: Executive Vice President and Chief Financial Officer|
| || |